PMID- 28937692
OWN - NLM
STAT- MEDLINE
DCOM- 20180119
LR  - 20200306
IS  - 1476-5578 (Electronic)
IS  - 1359-4184 (Print)
IS  - 1359-4184 (Linking)
VI  - 22
IP  - 10
DP  - 2017 Oct
TI  - BDNF at the synapse: why location matters.
PG  - 1370-1375
LID - 10.1038/mp.2017.144 [doi]
AB  - Neurotrophic factors, a family of secreted proteins that support the growth, 
      survival and differentiation of neurons, have been intensively studied for 
      decades due to the powerful and diverse effects on neuronal physiology, as well 
      as their therapeutic potential. Such efforts have led to a detailed understanding 
      on the molecular mechanisms of neurotrophic factor signaling. One member, 
      brain-derived neurotrophic factor (BDNF) has drawn much attention due to its 
      pleiotropic roles in the central nervous system and implications in various brain 
      disorders. In addition, recent advances linking the rapid-acting antidepressant, 
      ketamine, to BDNF translation and BDNF-dependent signaling, has re-emphasized the 
      importance of understanding the precise details of BDNF biology at the synapse. 
      Although substantial knowledge related to the genetic, epigenetic, cell 
      biological and biochemical aspects of BDNF biology has now been established, 
      certain aspects related to the precise localization and release of BDNF at the 
      synapse have remained obscure. A recent series of genetic and cell biological 
      studies have shed light on the question-the site of BDNF release at the synapse. 
      In this Perspectives article, these new insights will be placed in the context of 
      previously unresolved issues related to BDNF biology, as well as how BDNF may 
      function as a downstream mediator of newer pharmacological agents currently under 
      investigation for treating psychiatric disorders.
FAU - Song, M
AU  - Song M
AD  - Synaptic Circuit Plasticity Laboratory, Department of Structure and Function of 
      Neural Network, Korea Brain Research Institute, Dong-gu, Daegu, Korea.
FAU - Martinowich, K
AU  - Martinowich K
AD  - Lieber Institute for Brain Development, Baltimore, MD, USA.
AD  - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School 
      of Medicine, Baltimore, MD, USA.
AD  - Department of Neuroscience, Johns Hopkins University School of Medicine, 
      Baltimore, MD, USA.
FAU - Lee, F S
AU  - Lee FS
AD  - Department of Psychiatry, Sackler Institute for Developmental Psychobiology, 
      Weill Cornell Medical College of Cornell University, New York, NY, USA.
LA  - eng
GR  - R01 MH105592/MH/NIMH NIH HHS/United States
GR  - R01 NS052819/NS/NINDS NIH HHS/United States
PT  - Editorial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170725
PL  - England
TA  - Mol Psychiatry
JT  - Molecular psychiatry
JID - 9607835
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 690G0D6V8H (Ketamine)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/pharmacology
MH  - Brain/metabolism
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism/*physiology
MH  - Humans
MH  - Ketamine/pharmacology
MH  - Neuronal Plasticity/genetics
MH  - Neurons/metabolism
MH  - Signal Transduction/drug effects
MH  - Synapses/metabolism
PMC - PMC5646361
MID - NIHMS880137
COIS- Disclosure: The authors declare no conflict of interest.
EDAT- 2017/09/25 06:00
MHDA- 2018/01/20 06:00
PMCR- 2018/01/25
CRDT- 2017/09/23 06:00
PHST- 2017/01/17 00:00 [received]
PHST- 2017/04/13 00:00 [revised]
PHST- 2017/05/26 00:00 [accepted]
PHST- 2017/09/23 06:00 [entrez]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2018/01/20 06:00 [medline]
PHST- 2018/01/25 00:00 [pmc-release]
AID - mp2017144 [pii]
AID - 10.1038/mp.2017.144 [doi]
PST - ppublish
SO  - Mol Psychiatry. 2017 Oct;22(10):1370-1375. doi: 10.1038/mp.2017.144. Epub 2017 
      Jul 25.